BOSTON -- Data from two ongoing studies testing new
approaches for the treatment of chronic hepatitis C will be presented at the
annual meeting of the American Association for the Study of Liver Diseases
(AASLD) this afternoon.
Presented by principal investigator Nezam Afdhal, MD, chief of
hepatology at Beth Israel Deaconess Medical Center (BIDMC) and associate
professor of Medicine at Harvard Medical School, the new findings provide
researchers with sufficient evidence to demonstrate promising results for
hepatitis C patients who have not responded to existing therapies.
A viral infection, hepatitis C is transmitted through exposure to infected
blood. The virus, which affects an estimated 4 million individuals nationwide,
is able to survive and flourish inside the body by taking up residence in the
liver cells, and subsequently using the cells' inner machinery to make more
copies of the virus. These in turn, infect other healthy cells.
The standard treatment for hepatitis C is a combination of interferon alfa
and ribavirin, which act as anti-viral agents to eradicate the virus.
According to Afdhal, the most recent advance in treatment has been the
pegylation of interferon, which enables a once-a-week administration of the
protein by injection and improves the ability to clear the virus. Combination
therapy with pegylated interferon plus ribavirin for 24 to 48 weeks can result
in eradication of the virus in about 50 percent of patients, he adds.
"When the hepatitis C virus doesn't respond -- as occurs in about half of
all patients who are treated -- those patients who already have cirrhosis are
at a far greater risk for developing liver cancer or suffering liver failure,"
notes Afdhal. In fact, he says, hepatitis C is the leading cause of liver
transplants in the U.S. Until now, no treatment has been available for these
patients.
In his first presentation, Afdhal will describe results from the COPILOT
(Colchicine versus PEG-INTRON Long-Term) study, which was designed by Afdhal
and colleagues at BIDMC to test the long-term use of low-dose interferon among
hepatitis C patients. Conducted at 40 sites nationwide, the findings are the
first to demonstrate that the progression of hepatitis C can be prevented or
delayed through long-term maintenance therapy with peginterferon alfa-2b.
According to Afdhal, researchers found that peginterferon alfa-2B reduced
by 50 percent the risk of patients reaching a clinical endpoint (variceal
bleeding, liver failure, liver transplantation, hepatocellular carcinoma or
death) and reported the results as part of a planned two-year interim analysis
of the data.
"This is a new treatment paradigm, showing for the first time that we can
prevent the serious complications of liver disease," he explains. "The results
found that when used in this way, the therapy reduced by half the risk of the
virus advancing to cause liver damage."
The COPILOT study tested weight-based low-dose peginterferon alfa-2b (0.5
mcg/kg/wk, injected subcutaneously) against colchicine (0.6 mg orally, twice
daily), an anti-inflammatory and antifibrotic medication, in 550 chronic
hepatitis C patients with advanced fibrosis who had previously failed
interferon-based therapies. A total of 59 patients reached a clinical
verified endpoint: 39 in the colchicine group versus 20 in the peginterferon
alfa-2b group (p=0.003). The annual clinical event rate was approximately
five percent (7.0 percent vs. 3.5 percent for colchicine and peginterferon
alfa-2b, respectively), underscoring the need for better treatments to prevent
disease progression.
Afdhal noted that the low 0.5 mcg/kg weekly dose of peginterferon alfa-2b
used in the study -- one-third the dose used in standard combination therapy
-- was well tolerated by patients and spared them the side effect of
developing hemolytic anemia, which is often associated with ribavirin use.
"Patient adherence to their prescribed regimen is critical to success in
hepatitis treatment and is an important consideration for long-term
maintenance therapy," he said.
The COPILOT study was supported by Schering-Plough Corporation,
manufacturer of peginterferon alfa-2b.
Afdhal's second presentation will describe results from a Phase II
clinical trial of a new antiviral agent, NM283, being tested in humans for the
first time.
The new drug shows activity against hepatitis C genotype 1 (HCV). One of
six genotypes in existence, genotype 1 is the most predominant strain in the
U.S., Japan and Western Europe, and is particularly difficult to treat.
Unlike existing therapies, which are administered by injection, NM283 is
taken orally, says Afdhal, adding that it also has fewer side effects than
existing agents. NM283 is the first in a new class of designer drugs, a
polymerase inhibitor, specifically designed to block a step in HCV viral
replication.
"This drug is a new class of treatment for HCV and represents significant
hope for future therapies," he noted. "Data from these clinical trials are
encouraging and suggest that NM283 may prove to be another treatment option
(for hepatitis C patients)."
NM283 was shown to have direct and significant antiviral activity against
HCV as a single agent in both Phase I and Phase II clinical trials. Combining
NM283 with interferon also showed promising activity, according to Afdhal.
NM283 was developed by Idenix Pharmaceuticals, Inc., which sponsored the
Phase II clinical trial.
Beth Israel Deaconess Medical Center is a major patient care, teaching and
research affiliate of Harvard Medical School, and ranks third in National
Institutes of Health funding among independent hospitals nationwide. BIDMC is
clinically affiliated with the Joslin Diabetes Center and is a research
partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital
of the Boston Red Sox.
Source: Beth Israel Deaconess Medical Center
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.